Nature Medicine, Published online: 25 June 2026; doi:10.1038/s41591-026-04471-x
In the ongoing phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) trial in patients with transplant-eligible, newly diagnosed multiple myeloma, induction with the BCMA×CD3 bispecific engager teclistamab in combination with daratumumab plus lenalidomide, with or without bortezomib, had a similar toxicity profile to other bispecific regimens with an encouraging and deep response rate.